TABLE 1.

Population Estimates for Eligible Patients with Nonmyeloid Malignancies Treated with Myelosuppressive Chemotherapy and Patient-Administered Short-Acting G-CSFs

Parameter	Estimated Value, %	Eligible Population, n	Source/References
Health plan members	100.0	1,000,000	Assumption
Prevalence of nonmyeloid malignancies	4.3	43,000	U.S. Census46 SEER47
Treated with myelosuppressive chemotherapy	80.0	34,400	Culacova et al.49 Crawford et al.61
Using any G-CSF	45.0	15,480	Culacova et al.49 Denduluri et al.50
Using short-acting G-CSF	70.0	10,836	Griffiths et al.48
Patients self-administering short-acting G-CSF	20.0	2,167	Assumption

G-CSF = granulocyte colony-stimulating factor; SEER=Surveillance, Epidemiology, and End Results Program.